These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38524957)

  • 1. Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis.
    Gupta D; Singh A
    Indian J Psychol Med; 2024 Jan; 46(1):14-23. PubMed ID: 38524957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials.
    Rehan ST; Siddiqui AH; Khan Z; Imran L; Syed AA; Tahir MJ; Jassani Z; Singh M; Asghar MS; Ahmed A
    Ann Med Surg (Lond); 2022 Jul; 79():104115. PubMed ID: 35860157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
    Monahan C; McCoy L; Powell J; Gums JG
    Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder.
    Pham H; Warlick H; Bermudez R; Nguyen Q; Rey JA
    J Pharm Technol; 2022 Oct; 38(5):304-313. PubMed ID: 36046346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
    Corrao MM; Nelson LA
    CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone (depot) for schizophrenia.
    Sampson S; Hosalli P; Furtado VA; Davis JM
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD004161. PubMed ID: 27078222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
    Faden J; Serdenes R; Citrome L
    Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.
    Yagoda S; Graham C; Simmons A; Arevalo C; Jiang Y; McDonnell D
    CNS Spectr; 2021 Aug; 26(4):383-392. PubMed ID: 32393412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine and samidorphan combination treatment: A systematic review.
    Jawad MY; Alnefeesi Y; Lui LMW; Ceban F; Chen-Li DCJ; Teopiz K; Jaberi S; Gillissie ES; Vincenzo JDD; Rosenblat JD; McIntyre RS
    J Affect Disord; 2022 Mar; 301():99-106. PubMed ID: 35007644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Zhornitsky S; Brunelle S; Stip E
    Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
    Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N
    Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
    Potkin SG; Kunovac J; Silverman BL; Simmons A; Jiang Y; DiPetrillo L; McDonnell D
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
    Sun L; McDonnell D; von Moltke L
    Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.